These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33677711)

  • 41. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
    Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
    Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
    Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
    Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G; Hamid M; Jalaeikhoo H
    Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
    Zhang J; Wang Y; Wang J; Hu J; Chen S; Jin J; Liu T; Zhou J; Hu Y; Ma D; Huang X; Ji C; Hou M
    Blood Cancer J; 2018 Jun; 8(7):61. PubMed ID: 29915172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR].
    Larripa I; Ruiz MS; Gutiérrez M; Bianchini M
    Medicina (B Aires); 2017; 77(1):61-72. PubMed ID: 28140313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].
    Gendron N; Belhouachi N; Morel V; Azgui Z; Maloum K; Nguyen-Khac F; Cayuela JM; Davi F; Merle-Béral H; Chapiro E
    Ann Biol Clin (Paris); 2014; 72(3):359-66. PubMed ID: 24876147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-Term Molecular Remission after Treatment with Imatinib in a Chronic Myeloid Leukemia Patient with Extreme Thrombocytosis Harboring Rare e14a3 (b3a3) BCR::ABL1 Transcript: A Case Report.
    Zhang X; Sun H; Su Y; Yi H
    Curr Oncol; 2022 Oct; 29(11):8171-8179. PubMed ID: 36354705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.
    Stein AM; Martinelli G; Hughes TP; Müller MC; Beppu L; Gottardi E; Branford S; Soverini S; Woodman RC; Hochhaus A; Kim DW; Saglio G; Radich JP
    BMC Cancer; 2013 Apr; 13():173. PubMed ID: 23547655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M; Evtimova D; Saussele S; Castagnetti F; Cervantes F; Janssen J; Hoffmann VS; Gugliotta G; Hehlmann R; Hochhaus A; Hasford J; Baccarani M
    J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.
    Huet S; Cony-Makhoul P; Heiblig M; Tigaud I; Gazzo S; Belhabri A; Souche D; Michallet M; Magaud JP; Hayette S; Nicolini F
    PLoS One; 2014; 9(9):e106250. PubMed ID: 25203717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular Analysis.
    Burmeister T; Bullinger L; le Coutre P
    Acta Haematol; 2023; 146(5):413-418. PubMed ID: 37231781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Kockerols C; Valk PJM; Janssen JJWM; Hogenbirk P; Cornelissen JJ; Saussele S; Spiess B; Perusini MA; Kim D; Westerweel PE
    Eur J Haematol; 2024 Nov; 113(5):606-613. PubMed ID: 38994654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
    Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
    Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.